Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization

Bone Marrow Transplantation

Volumn 23, Issue 12, 1999, Pages 1223-1228

  Reiser, M ^a   Josting, A ^a   Draube, A ^a   Mapara, M Y ^b   Scheid, C ^a   Chemnitz, J ^a   Tesch, H ^a   Wolf, J ^a   Diehl, V ^a   Sohngen D ^a   Engert, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CD34+ cells; Cyclophosphamide; Etoposide; Mobilization failure; Stem cell mobilization; Stem cell transplantation

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CELL COUNT; CELL SEPARATION; CLINICAL ARTICLE; CYTAPHERESIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

EID: 0033516303     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701791     Document Type: Article

References (30)

1. 2 plus rhG-CSF for mobilization of circulating progenitor cells in malignant lymphomas. Int J Artif Org 1993; 5: 30-34.
2. Rosenfeld CS, Shadduck RK, Zeigler ZR et al. Cyclophosphamide-mobilized peripheral blood stem cells in patient with lymphoid malignancies. Bone Marrow Transplant 1995; 15: 433-438.
3. Watts MJ, Sullivan AM, Jamieson E et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535-546.
4. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
5. Tarella C, Caracciolo D, Gavarotti P et al. Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization. Bone Marrow Transplant 1995; 16: 223-228.
6. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11-17.
7. Olivieri A, Offidani M, Ciniero L et al. PBSC collection after high-dose chemotherapy followed by G-CSF in patients with malignancies: analysis of results regarding factors affecting the yield of hemopoietic progenitors. Int J Artif Org 1993; 5: 57-63.
8. Tarella C, Castellino C, Cherasco C et al. Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome. Br J Haematol 1997; 99: 41-46.
9. Moskowitz CH, Classman JR, Wuest D et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-316.
10. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-3978.
11. Liberti G, Pearce R, Taghipour G et al. Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT. Am Oncol 1994; 2: 151-153.
12. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
13. Engert A, Josting A, Mapara M et al. High-dose sequential chemotherapy and autologous stem cell support for relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma - first results from an ongoing multicenter pilot study. Leuk Lymphoma 1998; 29 (Suppl. 1): 152 (Abstr.).
14. Pfreundschuh MG, Rueffer U, Lathan B et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994; 12: 580-586.
15. Josting A, Katay I, Rueffer U et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 1998; 9: 289-295.
16. Bender JG, Unverzagt KL, Walker DE. Identification and comparison of CD34 positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood 1991; 77: 2591-2596.
17. Leary AG, Ogawa M, Strauss LC. Single cell origin of multilineage colonies in culture. J Clin Oncol 1984; 84: 2193-2196.
18. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
19. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
20. Schmitz N, Sextro M, Hasenclever D et al. HD-R1 first results of a randomized trial comparing aggressive chemotherapy with high-dose therapy and hematopoietic stem cell transplantation in patients with chemosensitive relapse of Hodgkin's disease. Blood 1997; 10 (Suppl. 1): 115a (Abstr.).
21. Pettengell R, Testa NG, Swindell R et al. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993; 82: 2239-2248.
22. McQuaker IG, Haynes AP, Stainer C et al. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol 1997; 98: 228-233.
23. Zeller W, Gutensohn K, Stockschlader M et al. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. Bone Marrow Transplant 1996; 17: 709-713.
24. Indovina A, Majolino I, Scime R et al. High dose cyclophosphamide: stem cell mobilizing capacity in 21 patients. Leuk Lymphoma 1994; 14: 71-77.
25. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-697.
26. Demirer T, Buckner CD, Storer B et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J. Clin Oncol 1997; 15: 684-690.
27. Copelan EA, Ceselski SK, Ezzone SA et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997; 15: 759-765.
28. Watanabe S, Mukaiyama T, Ogawa Y et al. Peripheral blood stem cell mobilization with chemotherapy and granulocyte-colony stimulating factor in patients with hematological malignancies. Tokai J Exp Clin Med 1994; 19: 143-155.
29. Gianni AM, Bregni M, Siena S et al. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J Clin Oncol 1992; 10: 1955-1962.
30. Pucci G, Irrera G, Martino M et al. High-dose etoposide enables the collection of peripheral blood stem cells in patients who failed cyclophosphamide-induced mobilization. Br J Haematol 1998; 100: 612-613.